Failed clinical trials don’t always spell doom for a new drug. Here’s why
A failed trial isn’t always an automatic deal killer for a new drug, as clinical trials analyst Frank David explains in a new STAT Report.
This article was adapted from STAT’s latest report, “Failed trial, successful drug: how a negative readout can still lead to FDA approval.”
When a clinical trial readout for what seemed a promising drug comes back negative, investors often contemplate jumping ship and companies wonder if continuing to pursue regulators’ approval is worth the trouble.
What's Your Reaction?
